Drug
Alks 3831
Alks 3831: highest development phase Phase 3, developed by Alkermes. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 3831 NCT02873208 | Phase 3 | Schizophrenia |
| ALKS 3831 NCT02669758 | Phase 3 | Schizophrenia |
| ALKS 3831 NCT03201757 | Phase 3 | Schizophrenia |
| ALKS 3831 NCT02804568 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Alks 3831 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.